Artivion Completes Acquisition of Endospan

May 19, 2026—Artivion, Inc. announced that it has completed the acquisition of its long-standing partner Endospan Ltd. On May 8, Artivion announced it was exercising its option to acquire Endospan.

Endospan is the developer of the Nexus aortic arch system. The transaction includes a $135 million upfront net purchase price for Endospan as well as potential additional consideration contingent on commercial performance, noted the Artivion press release.

Artivion stated that the Nexus branched endovascular stent graft system received FDA approval in April 2026. Artivion advised that it has acted as the exclusive distributor of the Nexus system across Europe, Middle East, and Africa markets since 2019.

The company noted that the Nexus device joins Artivion’s portfolio of aortic arch solutions, including the AMDS hybrid prosthesis for aortic arch remodeling in the treatment of acute DeBakey type I aortic dissections and the Arcevo left subclavian artery (LSA) hybrid stent graft system.

Pat Mackin, Chairman, President, and Chief Executive Officer of Artivion, addressed the transaction in the company’s press release.

“Our acquisition of Endospan and its Nexus system completes our market-leading, three-pronged aortic arch portfolio,” commented Mackin. “This technology, alongside AMDS and Arcevo LSA, positions us at the forefront of this segment as the only company globally with a complete portfolio of aortic arch solutions. Further, Nexus is a platform technology, not just a single product. With this acquisition, we are also adding a robust pipeline of next-generation arch technologies currently in development that we expect will further expand and strengthen our leadership position in the aortic arch market over time.”